Cannabis Report
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 5/27/2018 4:38:22 PM - Followers: 205 - Board type: Free - Posts Today: 17

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

Cannabis Report
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Securities Registration Statement (s-1) 05/24/2018 05:04:19 PM
CVM News: CEL-SCI Corporation to Present at the 8th Annual LD Micro Invitational 05/22/2018 08:00:00 AM
CVM News: Current Report Filing (8-k) 05/21/2018 05:16:35 PM
CVM News: Quarterly Report (10-q) 05/15/2018 06:14:02 PM
CVM News: CEL-SCI Corporation Reports Second Quarter Fiscal 2018 Financial Results 05/15/2018 04:20:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#12411  Sticky Note Vienna, VA, January 3, 2018 -- CEL-SCI Foxwoods Man 01/03/18 08:19:00 AM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#13759   I’d think in case of loss; they would learning curve 05/27/18 04:38:22 PM
#13758   Nope I didn’t. Once trump opened his mouth learning curve 05/27/18 04:33:26 PM
#13757   Not sure if there is a connection between learning curve 05/27/18 04:30:01 PM
#13756   No, but without spelling out every detail I learning curve 05/27/18 04:24:35 PM
#13755   CVM setting up for blue sky breakout into TrendTrade2016 05/27/18 01:47:30 PM
#13754   An arbitration win will mainly benefit Geert and steve2150 05/27/18 01:02:54 PM
#13753   Hopefully we WILL get an arb decision...otherwise it Foxwoods Man 05/27/18 11:26:29 AM
#13752   Yes, I jumped to conclusions when I saw Turney 05/27/18 11:20:22 AM
#13751   ...or it could be, as clearly stated, a Foxwoods Man 05/27/18 11:02:38 AM
#13750   I think Motley Fool has a story about Turney 05/27/18 10:07:51 AM
#13749   My remark was more so that if a pijoe 05/27/18 10:05:35 AM
#13748   yes i do remember that post. where you warfaretrader 05/27/18 07:55:33 AM
#13747   "It’s like the poster who mentioned previous r/s zeezeeman 05/27/18 04:15:29 AM
#13746   As a class-action there might be a case lightrock 05/27/18 02:20:13 AM
#13745   I remember looking at it. No deep dive. lightrock 05/27/18 02:13:44 AM
#13744   On another note...I had some time and did learning curve 05/27/18 01:11:31 AM
#13743   Not a good point. This isn’t a car learning curve 05/27/18 12:50:33 AM
#13742   I had bought back at 2.76. There was learning curve 05/26/18 02:56:48 PM
#13741   Great point pijoe 05/26/18 12:39:34 PM
#13740   Regarding the issue of the insurance company paying, Kpauliukonis 05/26/18 12:22:26 PM
#13739   Should it be a winning arbitration, how long pijoe 05/26/18 11:02:30 AM
#13738   I was just playing with you LC, you warfaretrader 05/26/18 08:17:37 AM
#13737   Here, I made a google sheet lightrock 05/26/18 04:46:14 AM
#13736   look how tight that is, this is the lightrock 05/26/18 01:54:09 AM
#13735   Yep, if the monthly enrollment is right... lightrock 05/26/18 01:36:17 AM
#13734   If I do the 10% thing with the lightrock 05/26/18 01:07:02 AM
#13733   If I do it the long way, redoing lightrock 05/25/18 11:57:44 PM
#13732   Hey, look at this one lightrock 05/25/18 11:27:58 PM
#13731   It’s not 100% full proof. As nothing is. learning curve 05/25/18 04:16:34 PM
#13730   And CVMs is completed. Largest ever. Orphan trickledownfacists 05/25/18 03:37:32 PM
#13729   It's a race to many finish lines. RobotDroid 05/25/18 03:35:02 PM
#13728   2 cents, not even intended as a suggestion... lightrock 05/25/18 03:33:17 PM
#13727   Yup...that was posted a few hours ago. Multikine Foxwoods Man 05/25/18 03:27:18 PM
#13726   https://www.healio.com/hematology-oncology/head-neck-cancer/news/print/hemonc-to RobotDroid 05/25/18 03:21:18 PM
#13725   Very interesting, thx lightrock 05/25/18 02:45:31 PM
#13724   Sometimes crows are eaten. But never tastey.. pijoe 05/25/18 02:44:12 PM
#13723   There is a possibility of arbitration ruling after yankeesnyc27 05/25/18 02:43:38 PM
#13722   Hmmmm..... not so sure trickledownfacists 05/25/18 02:42:05 PM
#13721   me thinks your signal is broke LC, or warfaretrader 05/25/18 02:39:31 PM
#13720   Arbitration speculative winnings on a lawsuit.. pijoe 05/25/18 02:37:40 PM
#13719   If there is an alert of "stop trading" sab63090 05/25/18 02:37:26 PM
#13718   Busting out - what's up here puffadder 05/25/18 02:34:31 PM
#13717   Bump trickledownfacists 05/25/18 02:31:56 PM
#13716   After hours trading on CVM stops at 8PM. yankeesnyc27 05/25/18 02:30:56 PM
#13715   Couple bigger orders coming pijoe 05/25/18 02:30:14 PM
#13714   Release the Kraken! Mtzzz 05/25/18 02:22:33 PM
#13713   Ergomed also received shares recently . yankeesnyc27 05/25/18 02:21:20 PM
#13712   I would be nice to have an influx sab63090 05/25/18 02:19:10 PM
#13711   No trickledownfacists 05/25/18 02:18:31 PM
#13710   Can we assume Ergomed isn't stupid? yankeesnyc27 05/25/18 02:16:52 PM
PostSubject